Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409358 | 1.00 | TDP1 (0.41) | TDP1L3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8312302 | 0.84 | SLC6A4 (0.46) | — | |
| SCHEMBL409360 | 0.83 | MAOB (0.41) | TDP1CYP3A4CYP2D6DRD2DRD3 | |
| SCHEMBL1673004 | 0.81 | MAOB (0.44) | L3MBTL1DRD2DRD3MAOB | |
| SCHEMBL409787 | 0.81 | MAOB (0.44) | L3MBTL1DRD2DRD3MAOB | |
| SCHEMBL14546658 | 0.78 | MAOB (0.42) | L3MBTL1DRD2DRD3MAOB | |
| SCHEMBL6578347 | 0.78 | TDP1 (0.51) | TDP1L3MBTL1RAB9AMAOBMAPK1 | |
| SCHEMBL408911 | 0.76 | TDP1 (0.49) | TDP1L3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4836403 | 0.76 | SLC6A4 (0.43) | — | |
| SCHEMBL7306627 | 0.75 | ALDH1A1 (0.45) | L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940841-B9 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET SA (FR) | 2017-04-19 | — | — | EP | disclosed |
| EP-1940841-B1 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET SA (FR) | 2016-12-07 | — | — | EP | disclosed |
| US-9402924-B2 | Diagnostic compounds for targeting a chemokine receptors | GUERBET (FR) | 2016-08-02 | — | — | US | disclosed |
| US-9402924-B2 | Diagnostic compounds for targeting a chemokine receptors | GUERBET (FR) | 2016-08-02 | — | — | US | disclosed |
| EP-2474553-B1 | Compounds for diagnosing apoptosis | GUERBET SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8367039-B2 | Compounds for the diagnosis of diseases associated with VCAM expression | GUERBET (FR) | 2013-02-05 | — | — | US | disclosed |
| US-8367039-B2 | Compounds for the diagnosis of diseases associated with VCAM expression | GUERBET (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
| EP-2137209-B1 | COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH VCAM EXPRESSION | GUERBET SA (FR) | 2011-02-09 | — | — | EP | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20090202435-A1 | Diagnostic compounds for targeting a chemokine receptors | GUERBET (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090202435-A1 | Diagnostic compounds for targeting a chemokine receptors | GUERBET (FR) | 2009-08-13 | — | — | US | disclosed |
| WO-2008125420-A2 | COMPOUNDS FOR DIAGNOSING APOPTOSIS | GUERBET (FR) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125464-A1 | COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH VCAM EXPRESSION | GUERBET (FR) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007042504-A2 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET (FR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | KLK3, IGF1R, GIPR | TDP1 4424/4885L3MBTL1 3039/4885CYP3A4 4470/4885 |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | TPX2, VIP, BAX | TDP1 2101/4885L3MBTL1 103/4885CYP3A4 4117/4885 |
| US-20090202435-A1 | Diagnostic compounds for targeting a chemokine receptors | CCL2, ACKR3, CCR5 | TDP1 4553/4885L3MBTL1 4179/4885CYP3A4 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.